Nothing Special   »   [go: up one dir, main page]

MX2009007334A - 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity. - Google Patents

6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.

Info

Publication number
MX2009007334A
MX2009007334A MX2009007334A MX2009007334A MX2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A MX 2009007334 A MX2009007334 A MX 2009007334A
Authority
MX
Mexico
Prior art keywords
sphingosine
biological activity
phosphate
carboxylic acid
acid amide
Prior art date
Application number
MX2009007334A
Other languages
Spanish (es)
Inventor
Richard L Beard
Haiging Yuan
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2009007334A publication Critical patent/MX2009007334A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1 -phosphate receptor agonist and or antagonist biological activity: Formula (I) and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.
MX2009007334A 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity. MX2009007334A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88447007P 2007-01-11 2007-01-11
PCT/US2008/050695 WO2008089015A1 (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Publications (1)

Publication Number Publication Date
MX2009007334A true MX2009007334A (en) 2009-07-15

Family

ID=39399972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007334A MX2009007334A (en) 2007-01-11 2008-01-10 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.

Country Status (8)

Country Link
EP (1) EP2125723A1 (en)
JP (1) JP2010515750A (en)
KR (1) KR20090101307A (en)
CN (1) CN101668741A (en)
AU (1) AU2008206495A1 (en)
CA (1) CA2674946A1 (en)
MX (1) MX2009007334A (en)
WO (1) WO2008089015A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524917B2 (en) 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
EP2262497A2 (en) * 2008-03-17 2010-12-22 Allergan, Inc. S1p3 receptor inhibitors for treating inflammation
KR20210099206A (en) 2008-07-23 2021-08-11 아레나 파마슈티칼스, 인크. SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
SI2342205T1 (en) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (en) 2010-03-03 2016-01-13 艾尼纳制药公司 Prepare the method for S1P1 receptor modulators and crystalline form thereof
TWI522361B (en) * 2010-07-09 2016-02-21 艾伯維公司 Fused heterocyclic derivative as S1P regulator
CN105073728A (en) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
KR20230151072A (en) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. Methods of treating conditions related to the s1p1 receptor
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
KR20190113955A (en) 2017-02-16 2019-10-08 아레나 파마슈티칼스, 인크. Compounds and Methods for the Treatment of Inflammatory Bowel Disease With Extra-Intestinal Symptoms
CN110483437B (en) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 Five-membered ring-containing compound and preparation and application thereof
JP7397011B2 (en) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Methods of treating conditions associated with S1P1 receptors
KR20210074291A (en) 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. Compounds useful for the treatment of autoimmune and inflammatory disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2121394A1 (en) 1971-01-08 1972-08-25 Anvar 2-methyl indole 3-carboxylic acid amides - antiinflammatories analgesics, tranquillisers, fungicides, herbicides and inters
EP0146810A3 (en) 1983-12-05 1987-05-13 Solco Basel AG Process for the preparation of sphingosin derivatives
US5110987A (en) 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
ATE216384T1 (en) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1998040349A1 (en) 1997-03-12 1998-09-17 Takara Shuzo Co., Ltd. Sphingosine analogues
US6239297B1 (en) 1997-09-11 2001-05-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
DE19753522A1 (en) * 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituted indoles, their preparation and their use as pharmaceuticals
EA200100774A1 (en) * 1999-01-13 2002-02-28 Милленниум Фамэсьютикэлс, Инк. HYDRONIC
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
ATE367812T1 (en) 2001-06-20 2007-08-15 Wyeth Corp SUBSTITUTED INDOLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
JPWO2003070691A1 (en) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 N-hydroxycarboxamide derivatives
EP1984334B1 (en) 2006-02-15 2014-04-09 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity

Also Published As

Publication number Publication date
CA2674946A1 (en) 2008-07-24
KR20090101307A (en) 2009-09-24
JP2010515750A (en) 2010-05-13
WO2008089015A1 (en) 2008-07-24
EP2125723A1 (en) 2009-12-02
AU2008206495A1 (en) 2008-07-24
CN101668741A (en) 2010-03-10

Similar Documents

Publication Publication Date Title
MX2009007334A (en) 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.
MX2010007588A (en) 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity.
WO2007112322A3 (en) Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
WO2007095561A3 (en) Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
WO2009035997A3 (en) Benzo-fused heterocycles
TNSN08089A1 (en) Substituted benzimidazoles and methods of preparation
NO20091599L (en) Chemical connections
NO20065327L (en) Process for the preparation of derivatives of 5- [4- (2-hydroxy-propyl) -3,5-dihydro-3H'1, 2,4 (triazin-2-yl) -benzamide.
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators
NO20090581L (en) Hydroxylated and methoxylated cyclopenta [D] pyrimidines as AKT protein kinase inhibitors
MX2010009752A (en) Oxadiazoanthracene compounds for the treatment of diabetes.
NO20085385L (en) Thiazole compounds such as cannabinoid receptor ligands and uses thereof
NO20091741L (en) Pyrazoline Compounds as Mineral Corticoid Receptor Antagonists
TW200745066A (en) Novel PTP1B inhibitors
NO20071314L (en) Peptidic vasopressin receptor agonists
ATE520651T1 (en) SUBSTITUTED PHENYLMETHYLBICYCLOCARBONIC ACID AMIDE COMPOUNDS
MY146606A (en) Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
EA201390717A1 (en) 3- (AMINOARIL) PYRIDINE CONNECTIONS
NO20084853L (en) Compounds that are agonists of muscarinic receptors and which may be effective in the treatment of pain, Alzheimer's disease and / or schizophrenia
WO2008059370A3 (en) Substituted bicyclocarboxyamide compounds
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
NO20091052L (en) Diaryl ether derivatives and uses thereof
WO2010123959A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MX2009004314A (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal